title: The role of statins in deep vein thrombosis.
abstract: Deep vein thrombosis (DVT) represents the formation of a blood clot in one of the deep veins of our body, predominantly occurring in the legs. According to international guidelines, the goal of the treatment in deep vein thrombosis is to prevent the progression and the recurrences of thrombotic process. The aim of this article is to explain the pathogenetic mechanism of deep vein thrombosis and the benefits of statins in such a disease. The vasoprotective effects of statins are related to their anti-thrombotic and anti-inflammatory properties. The administration of statins is associated with a lower incidence of venous thromboembolism (VTE) in the general population. It also helps in reducing the frequency of recurrences, being prescribed after an optimal 6 to 12 month anticoagulation. The study of these properties creates new opportunities for the use of statins in the prevention of post-thrombotic syndrome and recurrent venous thromboembolism (VTE).
authors.affiliation: Discipline of Medical Semiology, University of Medicine and Pharmacy Grigore T. Popa-Iaşi School of Medicine.
authors.forename: Maria-Magdalena
authors.initials: MM
authors.lastname: Leon
authors.forename: Elena
authors.initials: E
authors.lastname: Cojocaru
authors.forename: Roxana
authors.initials: R
authors.lastname: Cobzaru
authors.forename: Amalia
authors.initials: A
authors.lastname: Didii
authors.forename: F
authors.initials: F
authors.lastname: Mitu
mesh_terms: D050197:Atherosclerosis / Q000150:complications; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors